Our previous studies showed that VPA, at a safe therapeutic dose of 0.5 mM, sensitizes breast tumor MCF7 cells and the primary cultured breast tumor cells to IR by impeding HR function with Rad51 inhibition (33). This evidence concerns the gene RAD51 and breast neoplasm.